A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options

Myrto Moutafi, Dimitrios C. Ziogas, Spyros Michopoulos, Tina Bagratuni, Vassiliki Vasileiou, Laura Verga, Giampaolo Merlini, Giovanni Palladini, Charis Matsouka, Meletios A. Dimopoulos, Efstathios Kastritis

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CASE PRESENTATION: Among hereditary amyloidosis subtypes, we describe here a specific case of Apolipoprotein AI amyloidosis (AApoAI), where the diagnosis began from an almost asymptomatic hepatomegaly followed by the development of primary hypogonadism. Baseline laboratory tests showed increased liver enzymes, while imaging tests revealed a suspected infiltrative liver disease. Patient underwent into liver biopsy and histological examination detected the presence of periodic acid-Schiff (-) and Congo-red (+) amorphous eosinophilic material within normal liver tissue. In the typing of amyloid by immunoelectron microscopy, the liver appeared heavily infiltrated by anti-apoAI (+) amyloid fibrils. Gene sequencing and mutational analysis revealed a single-base mutation at position c.251 T > C resulting in an amino acid substitution from leucine to proline in the mature ApoAI protein. This amino acid change led to lower cleavage and ApoAI deposition into the involved organs. Few years later, our patient remaining without treatment, came with symptoms consistent with primary hypogonadism but testicular involvement with ApoAI deposits could not be proven since the patient refused testicular biopsy. Based on this case, we recap the diagnostic challenges, the clinical manifestations, and the potential treatment options for this indolent hereditary amyloidosis subtype. CONCLUSIONS: This case-report enlarges the clinical picture of ApoAI-driven disease and its complex genetic background and in parallel suggests for a more systematic approach in any case with strong suspicion of hereditary amyloidosis.

Original languageEnglish
Number of pages1
JournalBMC Medical Genetics
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 21 2019

Fingerprint

Familial Amyloidosis
Apolipoprotein A-I
Amyloidosis
Hypogonadism
Liver
Amyloid
Apolipoprotein C-II
Apolipoprotein C-III
Gelsolin
Apolipoprotein A-II
Biopsy
Cystatin C
Congo Red
Mutation
Periodic Acid
Prealbumin
Hepatomegaly
Immunoelectron Microscopy
Amino Acid Substitution
Therapeutics

Keywords

  • ApoAI amyloidosis
  • Immune-electron microscopy
  • Liver
  • Rare autosomal disease

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

A new genetic variant of hereditary apolipoprotein A-I amyloidosis : a case-report followed by discussion of diagnostic challenges and therapeutic options. / Moutafi, Myrto; Ziogas, Dimitrios C.; Michopoulos, Spyros; Bagratuni, Tina; Vasileiou, Vassiliki; Verga, Laura; Merlini, Giampaolo; Palladini, Giovanni; Matsouka, Charis; Dimopoulos, Meletios A.; Kastritis, Efstathios.

In: BMC Medical Genetics, Vol. 20, No. 1, 21.01.2019.

Research output: Contribution to journalArticle

Moutafi, Myrto ; Ziogas, Dimitrios C. ; Michopoulos, Spyros ; Bagratuni, Tina ; Vasileiou, Vassiliki ; Verga, Laura ; Merlini, Giampaolo ; Palladini, Giovanni ; Matsouka, Charis ; Dimopoulos, Meletios A. ; Kastritis, Efstathios. / A new genetic variant of hereditary apolipoprotein A-I amyloidosis : a case-report followed by discussion of diagnostic challenges and therapeutic options. In: BMC Medical Genetics. 2019 ; Vol. 20, No. 1.
@article{600188ad735442cba3282bb04d5f9f93,
title = "A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options",
abstract = "BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CASE PRESENTATION: Among hereditary amyloidosis subtypes, we describe here a specific case of Apolipoprotein AI amyloidosis (AApoAI), where the diagnosis began from an almost asymptomatic hepatomegaly followed by the development of primary hypogonadism. Baseline laboratory tests showed increased liver enzymes, while imaging tests revealed a suspected infiltrative liver disease. Patient underwent into liver biopsy and histological examination detected the presence of periodic acid-Schiff (-) and Congo-red (+) amorphous eosinophilic material within normal liver tissue. In the typing of amyloid by immunoelectron microscopy, the liver appeared heavily infiltrated by anti-apoAI (+) amyloid fibrils. Gene sequencing and mutational analysis revealed a single-base mutation at position c.251 T > C resulting in an amino acid substitution from leucine to proline in the mature ApoAI protein. This amino acid change led to lower cleavage and ApoAI deposition into the involved organs. Few years later, our patient remaining without treatment, came with symptoms consistent with primary hypogonadism but testicular involvement with ApoAI deposits could not be proven since the patient refused testicular biopsy. Based on this case, we recap the diagnostic challenges, the clinical manifestations, and the potential treatment options for this indolent hereditary amyloidosis subtype. CONCLUSIONS: This case-report enlarges the clinical picture of ApoAI-driven disease and its complex genetic background and in parallel suggests for a more systematic approach in any case with strong suspicion of hereditary amyloidosis.",
keywords = "ApoAI amyloidosis, Immune-electron microscopy, Liver, Rare autosomal disease",
author = "Myrto Moutafi and Ziogas, {Dimitrios C.} and Spyros Michopoulos and Tina Bagratuni and Vassiliki Vasileiou and Laura Verga and Giampaolo Merlini and Giovanni Palladini and Charis Matsouka and Dimopoulos, {Meletios A.} and Efstathios Kastritis",
year = "2019",
month = "1",
day = "21",
doi = "10.1186/s12881-019-0755-5",
language = "English",
volume = "20",
journal = "BMC Medical Genetics",
issn = "1471-2350",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A new genetic variant of hereditary apolipoprotein A-I amyloidosis

T2 - a case-report followed by discussion of diagnostic challenges and therapeutic options

AU - Moutafi, Myrto

AU - Ziogas, Dimitrios C.

AU - Michopoulos, Spyros

AU - Bagratuni, Tina

AU - Vasileiou, Vassiliki

AU - Verga, Laura

AU - Merlini, Giampaolo

AU - Palladini, Giovanni

AU - Matsouka, Charis

AU - Dimopoulos, Meletios A.

AU - Kastritis, Efstathios

PY - 2019/1/21

Y1 - 2019/1/21

N2 - BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CASE PRESENTATION: Among hereditary amyloidosis subtypes, we describe here a specific case of Apolipoprotein AI amyloidosis (AApoAI), where the diagnosis began from an almost asymptomatic hepatomegaly followed by the development of primary hypogonadism. Baseline laboratory tests showed increased liver enzymes, while imaging tests revealed a suspected infiltrative liver disease. Patient underwent into liver biopsy and histological examination detected the presence of periodic acid-Schiff (-) and Congo-red (+) amorphous eosinophilic material within normal liver tissue. In the typing of amyloid by immunoelectron microscopy, the liver appeared heavily infiltrated by anti-apoAI (+) amyloid fibrils. Gene sequencing and mutational analysis revealed a single-base mutation at position c.251 T > C resulting in an amino acid substitution from leucine to proline in the mature ApoAI protein. This amino acid change led to lower cleavage and ApoAI deposition into the involved organs. Few years later, our patient remaining without treatment, came with symptoms consistent with primary hypogonadism but testicular involvement with ApoAI deposits could not be proven since the patient refused testicular biopsy. Based on this case, we recap the diagnostic challenges, the clinical manifestations, and the potential treatment options for this indolent hereditary amyloidosis subtype. CONCLUSIONS: This case-report enlarges the clinical picture of ApoAI-driven disease and its complex genetic background and in parallel suggests for a more systematic approach in any case with strong suspicion of hereditary amyloidosis.

AB - BACKGROUND: Hereditary amyloidosis refers to a wide spectrum of rare diseases with different causative mutations in the genes of various proteins including transthyretin, apolipoprotein AI and AII, gelsolin, lysozyme, cystatin C, fibrinogen Aα-chain, β2-microglobulin, apolipoprotein CII and CIII. CASE PRESENTATION: Among hereditary amyloidosis subtypes, we describe here a specific case of Apolipoprotein AI amyloidosis (AApoAI), where the diagnosis began from an almost asymptomatic hepatomegaly followed by the development of primary hypogonadism. Baseline laboratory tests showed increased liver enzymes, while imaging tests revealed a suspected infiltrative liver disease. Patient underwent into liver biopsy and histological examination detected the presence of periodic acid-Schiff (-) and Congo-red (+) amorphous eosinophilic material within normal liver tissue. In the typing of amyloid by immunoelectron microscopy, the liver appeared heavily infiltrated by anti-apoAI (+) amyloid fibrils. Gene sequencing and mutational analysis revealed a single-base mutation at position c.251 T > C resulting in an amino acid substitution from leucine to proline in the mature ApoAI protein. This amino acid change led to lower cleavage and ApoAI deposition into the involved organs. Few years later, our patient remaining without treatment, came with symptoms consistent with primary hypogonadism but testicular involvement with ApoAI deposits could not be proven since the patient refused testicular biopsy. Based on this case, we recap the diagnostic challenges, the clinical manifestations, and the potential treatment options for this indolent hereditary amyloidosis subtype. CONCLUSIONS: This case-report enlarges the clinical picture of ApoAI-driven disease and its complex genetic background and in parallel suggests for a more systematic approach in any case with strong suspicion of hereditary amyloidosis.

KW - ApoAI amyloidosis

KW - Immune-electron microscopy

KW - Liver

KW - Rare autosomal disease

UR - http://www.scopus.com/inward/record.url?scp=85060207704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060207704&partnerID=8YFLogxK

U2 - 10.1186/s12881-019-0755-5

DO - 10.1186/s12881-019-0755-5

M3 - Article

VL - 20

JO - BMC Medical Genetics

JF - BMC Medical Genetics

SN - 1471-2350

IS - 1

ER -